Clinical Trial Update: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating PANZYGA in pediatric Chronic Immune Thrombocytopenia has been terminated; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Panzyga (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Chronic Immune Thrombocytopenia | Phase 4 | Status: TERMINATED | Results posted: 2024-08-07